Eli Lilly’s stock fell sharply on Thursday morning, despite beating analyst expectations for its first-quarter earnings. The pharmaceutical giant reported adjusted earnings per share of $3.34 and revenue that rose 45% year-over-year to $12.73 billion. However, the company lowered its full-year profit forecasts due to “net losses on investments in equity securities” and IPR&D charges.
Lilly had previously forecasted revenue between $58.0 to $61.0 billion for 2025, but revised its estimates downwards. The company’s sales of its blockbuster weight-loss drugs Mounjaro and Zepbound rose to $3.84 billion and $2.31 billion, respectively, topping expectations.
Despite the strong Q1 earnings, Eli Lilly shares plummeted over 7% shortly after markets opened, wiping out more than half of the day’s gains. The stock had entered the day up more than 16%.
Source: https://www.investopedia.com/eli-lilly-q1-fy2025-results-11724994